{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:14:32Z","timestamp":1753892072568,"version":"3.41.2"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Transcription factor binding to IGHM enhancer 3 (<jats:italic>TFE3<\/jats:italic>) fusion-related renal cell carcinoma (<jats:italic>TFE3<\/jats:italic>-RCC) is a rare subtype of RCC. Its pathogenesis is primarily associated with chromosomal translocations resulting in <jats:italic>TFE3<\/jats:italic> fusions. <jats:italic>TFE3<\/jats:italic>-RCC is most commonly observed in adolescents and young adults, with a higher incidence in women than in men. Typically, <jats:italic>TFE3<\/jats:italic>-RCC initially presents as painless hematuria, an abdominal mass, or with systemic symptoms. In recent years, with advancements in molecular diagnostic techniques, the diagnosis rate of <jats:italic>TFE3<\/jats:italic>-RCC has increased. However, extrarenal occurrences of <jats:italic>TFE3<\/jats:italic>-RCC remain rare. <jats:italic>PRCC<\/jats:italic> can fuse with <jats:italic>TFE3<\/jats:italic> causing <jats:italic>PRCC<\/jats:italic>-<jats:italic>TFE3<\/jats:italic> fusion-related RCC, a unique subtype of <jats:italic>TFE3<\/jats:italic>-RCC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>We report a case of <jats:italic>PRCC<\/jats:italic>-<jats:italic>TFE3<\/jats:italic> RCC in a 29-year-old woman who was hospitalized owing to a mass in her upper abdomen. To our knowledge, this is the second reported instance of an extrarenal occurrence. Imaging revealed a large mass in the left retroperitoneum, and postoperative pathology revealed that the tumor cells were either epithelioid- or spindle-shaped, with large nuclei, prominent nucleoli, and abundant chromatin. The cells were densely arranged in nests or sheets, with abundant eosinophilic or amphophilic cytoplasm. Immunohistochemical analysis revealed diffuse and strong nuclear positivity for <jats:italic>TFE3<\/jats:italic> but negativity for carbonic anhydrase IX (CAIX). Fluorescence <jats:italic>in situ<\/jats:italic> hybridization did not detect a <jats:italic>TFE3<\/jats:italic> break, but RNA sequencing confirmed the presence of a <jats:italic>PRCC-TFE3<\/jats:italic> fusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The diagnosis of <jats:italic>TFE3<\/jats:italic>-RCC requires a comprehensive evaluation of histological features, immunohistochemical markers, and molecular testing. <jats:italic>PRCC<\/jats:italic>-<jats:italic>TFE3<\/jats:italic> RCC is highly aggressive with a high recurrence rate and poor prognosis in adults. Surgical resection is the primary treatment for localized lesions. However, close follow-up is necessary owing to a high risk of recurrence and metastasis. Targeted therapies and immunotherapies are potential treatment options for patients with advanced or metastatic disease.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1592042","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T04:12:55Z","timestamp":1748491975000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Extrarenal TFE3 fusion-related renal cell carcinoma"],"prefix":"10.3389","volume":"15","author":[{"given":"Zhouliang","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kejun","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"B1","first-page":"2022","article-title":"Renal cell carcinoma: An overview of the epidemiology, diagnosis, and treatment","volume":"39","author":"Bahadoram","year":"2022","journal-title":"G Ital Nefrol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-023-04347-6","article-title":"Molecular differences in renal cell carcinoma between males and females","volume":"41","author":"Pallauf","year":"2023","journal-title":"World J Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.784993","article-title":"Xp11.2 translocation renal cell carcinoma with TFE3 rearrangement: Distinct morphological features and prognosis with different fusion partners","volume":"11","author":"Ge","year":"2021","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000631","article-title":"TFE3-fusion variant analysis defines specific clinicopathologic associations among Xp11 translocation cancers","volume":"40","author":"Argani","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.75008","article-title":"Metastatic extra renal (adrenal) TFE3 translocation-associated renal cell carcinoma","volume":"16","author":"Alayed","year":"2024","journal-title":"Cureus"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.24920\/J1001-9294.2017.040","article-title":"Extrarenal Wilms\u2019 tumor of the female genital system: A case report and literature review","volume":"32","author":"Cao","year":"2017","journal-title":"Chin Med Sci J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpurol.2020.07.016","article-title":"Extrarenal Wilms tumor in children: A retrospective observational case series","volume":"16","author":"Liang","year":"2020","journal-title":"J Pediatr Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.5858\/2001-125-1081-AEWTOI","article-title":"Adult extrarenal Wilms tumor occurring in the uterus","volume":"125","author":"Muc","year":"2001","journal-title":"Arch Pathol Lab Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2022.151908","article-title":"Renal cancer associated with Xp11.2 translocation\/TFE3 gene fusion: Clinicopathological analysis of 13 cases","volume":"58","author":"Feng","year":"2022","journal-title":"Ann Diagn Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154313","article-title":"TFE3-immunopositive papillary renal cell carcinoma: A clinicopathological, immunohistochemical, and genetic study","volume":"242","author":"Takamatsu","year":"2023","journal-title":"Pathol Res Pract"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.5414\/CN109619","article-title":"Renal cell carcinoma associated with Xp11.2 translocations\/TFE3 gene fusion: Report of 5 cases and literature review","volume":"91","author":"Wang","year":"2019","journal-title":"Clin Nephrol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-024-01291-2","article-title":"Comprehensive molecular characterization of TFE3-rearranged renal cell carcinoma","volume":"56","author":"Lee","year":"2024","journal-title":"Exp Mol Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e16076","article-title":"TFE3 gene rearrangement and protein expression contribute to a poor prognosis of renal cell carcinoma","volume":"9","author":"Lin","year":"2023","journal-title":"Heliyon"},{"key":"B14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00345-024-05290-w","article-title":"Prognostic implications and diagnostic significance of TFE3 rearrangement in renal cell carcinoma","volume":"42","author":"Mu\u00f1oz Bastidas","year":"2024","journal-title":"World J Urol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1592042\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T04:12:56Z","timestamp":1748491976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1592042\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":14,"alternative-id":["10.3389\/fonc.2025.1592042"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1592042","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"article-number":"1592042"}}